文献速递肿瘤 PET/CT

中期4'-[甲基-11C]-硫代胸腺嘧啶PET预测头颈部鳞癌放化疗反应:与[18F]FDG PET比较

Interim 4'-[methyl-11C]-thiothymidine PET for predicting the chemoradiotherapeutic response in head and neck squamous cell carcinoma: comparison with [18F]FDG PET.
PubMed 文献 · EJNMMI Res · 2021-02-10

该回顾性分析纳入32例头颈部鳞癌(HNSCC)患者,在治疗前及放化疗约40 Gy时行[11C]4DST和[18F]FDG PET/CT,比较两种显像预测放化疗反应的能力。结果显示[11C]4DST的ΔSUVmax、ΔPTV和ΔTLP在完全缓解(CR)组显著大于非CR组,而[18F]FDG各参数在两组间无显著差异;[11C]4DST ΔMTV为-90是非CR早期识别的最佳 cutoff 值。

要点

  • [11C]4DST中期PET的ΔSUVmax、ΔPTV、ΔTLP可区分CR与非CR。
  • [18F]FDG中期PET的ΔSUVmax、ΔMTV、ΔTLG在CR与非CR间无显著差异。
  • [11C]4DST ΔMTV为-90是非CR早期识别的最佳 cutoff 值。

核心结论

  • 中期[11C]4DST PET可能有助于预测HNSCC患者的放化疗反应,与[18F]FDG PET相比具有潜在优势。

研究设计与样本

  • 回顾性分析前瞻性收集的数据,共32例HNSCC患者,在治疗前和治疗中约40 Gy时行[11C]4DST和[18F]FDG PET/CT。
  • 测量SUVmax、[18F]FDG的MTV和TLG、[11C]4DST的PTV和TLP,MTV或PTV定义为SUVmax大于2.5的体积。
  • 计算从基线到中期PET的ΔSUVmax、ΔMTV或ΔPTV、ΔTLG或ΔTLP。
  • 放化疗结束后3个月无或证据表明有残留或复发疾病者分别归为完全缓解(CR)和非CR。

主要发现

  • 所有患者基线[11C]4DST和[18F]FDG PET原发肿瘤均显示摄取增高。
  • 所有患者中期[18F]FDG PET显示摄取增高,而18例患者中期[11C]4DST PET无摄取增高。
  • 放化疗后25例为CR组,7例为非CR组。
  • [11C]4DST ΔSUVmax、ΔPTV和ΔTLP在CR组显著大于非CR组(P=0.044、<0.001、<0.001)。
  • [18F]FDG ΔSUVmax、ΔMTV或ΔTLG在CR组与非CR组间无显著差异。

关键数值与推荐

  • [11C]4DST ΔMTV为-90是非CR早期识别的最佳 cutoff 值。
  • MTV或PTV定义为SUVmax大于2.5的体积。
  • 放化疗结束后3个月无残留或复发证据为CR,有证据为非CR。

临床怎么用

  • 对于HNSCC放化疗患者,可考虑在约40 Gy时行中期[11C]4DST PET,通过ΔSUVmax、ΔPTV、ΔTLP及ΔMTV评估早期反应。
  • [11C]4DST ΔMTV为-90可作为早期识别非CR的参考 cutoff 值。
  • 中期[18F]FDG PET的ΔSUVmax、ΔMTV、ΔTLG在本研究中未能区分CR与非CR。

局限性

  • 本研究为初步结果,样本量有限(32例),需进一步验证。
  • 本研究为回顾性分析前瞻性收集的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated the potential of interim 4'-[methyl-11C]thiothymidine ([11C]4DST) PET for predicting the chemoradiotherapeutic response for head and neck squamous cell carcinoma (HNSCC), in comparison with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET. METHODS: A total of 32 patients with HNSCC who underwent both [11C]4DST and [18F]FDG PET/CT before therapy (baseline) and at approximately 40 Gy point during chemoradiotherapy (interim) were available for a retrospective analysis of prospectively collected data. The baseline was treatment-naïve PET/CT scan as part of staging. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) from [18F]FDG PET or proliferative tumor volume (PTV) from [11C]4DST PET, and total lesion glycolysis (TLG) from [18F]FDG PET or total lesion proliferation (TLP) from [11C]4DST PET were measured. MTV or PTV was defined as the volume with an SUVmax greater than 2.5. The differences in SUVmax (ΔSUVmax), MTV (ΔMTV) or PTV (ΔPTV) and TLG (ΔTLG) or TLP (ΔTLP) from baseline to interim PET scans were calculated. Patients without or with evidence of residual or recurrent disease at 3 months after completion of chemoradiotherapy were classified as showing a complete response (CR) and non-CR, respectively. RESULTS: All patients showed increased uptake in primary tumor on baseline [11C]4DST and [18F]FDG PET studies. All patients showed increased uptake on interim [18F]FDG PET, whereas 18 patients showed no increased uptake on interim [11C]4DST PET. After chemoradiotherapy, 25 patients were found to be in CR group and 7 to be in non-CR group. [11C]4DST ΔSUVmax, ΔPTV, and ΔTLP for CR group showed significantly greater reductions than the corresponding values for non-CR group (P = 0.044, < 0.001, < 0.001, respectively). However, there were no significant differences in [18F]FDG ΔSUVmax, ΔMTV, or ΔTLG between CR group and non-CR group. [11C]4DST ΔMTV of -90 was the best cutoff value for the early identification of patients with non-CR. CONCLUSION: These preliminary results suggest that interim [11C]4DST PET might be useful for predicting the chemoradiotherapeutic response in patients with HNSCC, in comparison with [18F]FDG PET.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Mitamura K, Norikane T, Yamamoto Y, et al. Interim 4'-[methyl-11C]-thiothymidine PET for predicting the chemoradiotherapeutic response in head and neck squamous cell carcinoma: comparison with [18F]FDG PET. EJNMMI Res. 2021. PMID: 33566186. doi:10.1186/s13550-021-00749-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。